ADORING is a phase 3 clinical study evaluating the safety and efficacy of tapinarof cream, 1% for the topical treatment of moderate to severe eczema in adults and children aged 2 years and above.
The study is an eight-week double-blind study in which participants will be randomized (chosen by chance) to receive tapinarof cream, 1% or a vehicle cream (the same cream but without tapinarof in it) to be applied once daily to areas of the skin suffering from moderate to severe eczema. Double-blind means that during the study, neither you nor your study doctor will know if you are receiving tapinarof cream or the vehicle cream.
Although several treatment options are available to treat eczema, we are evaluating tapinarof for application to large areas of the body for long periods of time. Tapinarof is an investigational non-steroidal product that is being evaluated to determine if it may help control eczema signs and symptoms.
If you choose to take part in this study, you will be one of approximately 400 adults and children aged 2 years and above who will be enrolled across approximately 60 sites in the US and Canada.
Study-related consultation and care
Study visits, tests, assessments, and procedures
Study treatment or vehicle cream
Male or female, 2 years of age or older
Have eczema that covers between 5% and 35% of their body, not including the scalp
NOTE: Participants with eczema only on their palms and soles are not eligible.
Been diagnosed with eczema for at least 6 months for those 6 years old and above or 3 months for those 2 to 5 years old
1. Bieber T. Atopic dermatitis. New England Journal of Medicine. 2008;358(14):1483-1494.
2. Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. Journal of the American Academy of Dermatology. 2014;70(2):338-351.
Although eczema is not contagious, it is a long-lasting and itchy inflammatory skin disease that impacts both the physical and psychological quality of life for the people who suffer from it.
Am I Eligible?